OGN logo

Organon & Co.

OGN
Healthcare|Drug Manufacturers - General|US
$13.87
+0.08 (+0.58%)
DCF Value
$30.78
Graham Number
$9.11
Cash / Share
$5.54
Next Earnings Report
Feb 11, 2027
EPS est. $0.92 · Revenue est. $1.54B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (2)

Dec 2027
Est. completion
P2Palmoplantar Keratoderma
Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
NCT06561321n=6
Dec 2027
Est. completion
P4Ovarian Stimulation
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT06175832n=60

Recent Press Releases

Organon Announces Quarterly Dividend
Oct 30, 2026 · Business Wire
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Oct 19, 2026 · Business Wire
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Oct 16, 2026 · Business Wire
Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold
Oct 13, 2026 · Accesswire
Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia
Oct 8, 2026 · Accesswire
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Oct 1, 2026 · Business Wire
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Sep 14, 2026 · Business Wire
Orogen Royalties Acquires the Serpent Gold Project in Nevada
Sep 10, 2026 · Accesswire
Orogen Royalties Acquires Two Gold Projects in Southwest Utah
Sep 2, 2026 · Accesswire
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Aug 27, 2026 · GlobeNewsWire

SEC Filings (59)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 30, 20268-KMaterial eventDocumentIndex
Oct 30, 202610-QQuarterly reportDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 31, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 31, 20268-KMaterial eventDocumentIndex
Jul 31, 202610-QQuarterly reportDocumentIndex
Jul 23, 20268-KMaterial eventDocumentIndex
Jul 17, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jun 17, 2026DEFM14AProxy / shareholder voteDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 11, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jun 1, 2026PREM14ADocumentIndex
May 29, 2026SDDocumentIndex
May 4, 202610-QQuarterly reportDocumentIndex
Apr 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 27, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 24, 202610-KAnnual reportDocumentIndex
Feb 20, 20268-KMaterial eventDocumentIndex
Feb 12, 20268-KMaterial eventDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Nov 10, 202510-Q/AQuarterly reportDocumentIndex
Nov 10, 202510-Q/AQuarterly reportDocumentIndex
Nov 10, 202510-K/AAnnual reportDocumentIndex
Nov 7, 20258-KMaterial eventDocumentIndex
Oct 30, 20258-K/AMaterial eventDocumentIndex
Oct 30, 2025SC 13G/APassive 5%+ stakeDocumentIndex